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Persistent viral infections including HCV, HBV, and HIV are associated with increased
immune regulatory pathways including the extrinsic FoxP3+CD4+ regulatoryT cells (Tregs)
and intrinsic inhibitory pathways such as programed death-1 (PD-1) and cytotoxic T lym-
phocyte antigen-4 (CTLA-4) with potentially reversible suppression of antiviral effector T
cells (1–12). Immunological consequences of viral coinfections relative to these immune
regulatory pathways and their interplay are not well-defined. In this study, we examined
the frequency, phenotype, and effector function of circulating T cell subsets in patients
with chronic HCV and/or HIV infection, hypothesizing that HCV/HIV coinfection will result
in greater immune dysregulation with pathogenetic consequences (13, 14). We show that
multiple T cell inhibitory pathways are induced in HCV/HIV coinfection including FoxP3+
Tregs, PD-1, and CTLA-4 in inverse association with overall CD4 T cell frequency but not
with liver function or HCV RNA titers.The inverse association between CD4T cell frequency
and their FoxP3, PD-1, or CTLA-4 expression remained significant in all subjects combined
regardless of HCV and/or HIV infection, suggesting a global homeostatic mechanism to
maintain immune regulation relative to CD4 T cell frequency. PD-1 blockade rescued T cell
responses to HIV but not HCV without significant impact by CTLA-4 blockade in vitro.
Collectively, these findings highlight complex immune interactions in viral coinfections
and differential regulatory pathways influencing virus-specific T cells that are relevant in
immunotherapeutic development.
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INTRODUCTION
FoxP3+CD4+ regulatory T cells (FoxP3+Tregs) play a key role in
mediating immune tolerance to self and non-self antigens includ-
ing viral pathogens (15). Programed death-1 (PD-1) and cytotoxic
T lymphocyte antigen-4 (CTLA-4) are receptors in CD28 family
of co-stimulatory molecules that are induced by T cell activation
and provide inhibitory signals to T cells (16). There are further
cross-talks between the “extrinsic” regulatory T cells (Tregs) and
“intrinsic” T cell co-stimulatory pathways (17, 18). In chronic
viral infection including HCV, increased circulating frequency of
CD4+FoxP3+ Tregs as well as increased PD-1 and/or CTLA-4
expression on virus-specific T cells have been reported (6, 7). Sim-
ilarly, HIV persists with dysfunctional antiviral effector T cells
with increased PD-1 and/or CTLA-4 expression (3, 19, 20). HIV
infection has also been associated with increased FoxP3+ Tregs in
peripheral CD4 T cell compartment despite HIV-associated CD4 T
cell loss in some (21–25) although not all studies (26–29). Further-
more, PD-1 and CTLA-4 expression in antiviral T cells correlated
with HIV viral load and CD4 T cell count in HIV-monoinfected
patients (3–5).
Further immune dysregulation may occur in HCV/HIV
coinfection due to HCV-mediated immune activation and
HIV-associated CD4 T cell loss (24, 30). Such interactions may
have clinical implications, given worsened outcomes in HCV/HIV-
coinfected patients (13, 14). However, potential interplays between
FoxP3+ Tregs and intrinsic T cell co-stimulatory pathways in
viral infections have not been well-defined. Moreover, it remains
unclear how they impact antiviral effector T cell response as well
as HCV and/or HIV-associated outcomes. These are relevant con-
siderations in immunotherapeutic development for chronic viral
infection (2–12, 31) as well as cancer patients with concurrent viral
infections (32).
In this study, we show that FoxP3+ Tregs are preserved in
the CD4 T cell compartment of HCV/HIV-coinfected patients
in direct association with PD-1 and CTLA-4 expression on CD4
T cells but not with liver function measures or HIV viremia.
Furthermore, FoxP3, PD-1, CTLA-4, CD28, and CD127 expres-
sion showed significant associations with the overall CD4 T
cell frequency, suggesting a global homeostatic mechanism to
maintain immune regulation as the size of CD4 T cell com-
partment changes. Finally, HIV-specific effector T cells were not
only more detectable in peripheral blood and but also more
responsive to PD-1 blockade in vitro, compared to HCV-specific
T cells.
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Table 1 | Patient groups.
Chronic HCV Chronic HCV/HIV Chronic HIV P -values***
C I/C I
n=20 n=23 n=21
Sex (M:F) 19:1 23:1 22:0 NA
Age (years)* 55 55 48 0.13
SALT (IU/ml)* 47 50 27 <0.0001
Total bilirubin (mg/dl)* 0.7 1.0 0.7 0.16
Albumin (g/dl)* 4.4 4.2 4.5 0.077
Platelets (103/mm3)* 197 205 201 0.85
INR* 1 1 1 0.67
APRI* 0.6 0.6 0.3 <0.0001
HCV genotype 1 (%) 85% 96% NA NA
median HCV RNA (IU/ml) 2,750,000 1,210,000 NA 0.98
HAART NA 87% 95% 0.61
Time from HIV diagnosis* NA 13 years 12 years 0.75
HIV viral load <50 NA 83% 61% 0.1
CD4 count** NA 407 586 0.043
*Median values.
**CD4 count in 16 HCV/HIV and 15 HIV patients peformed within 1month of immune analyses among HIV-infected patients.
***P-values by non-parametric Kruskal–Wallis for three groups and Mann–Whitney U for two groups.
NA (not applicable).
MATERIALS AND METHODS
STUDY SUBJECTS
Study subjects were recruited from the Hepatology and Infec-
tious Diseases clinics in the Philadelphia Veterans Affairs Medical
Center and the Hospital of the University of Pennsylvania with
informed consent approved by the institutional review board:
HCV-monoinfection (HCV, n= 20), chronic HCV/HIV coin-
fection (HCV/HIV, n= 23), chronic HIV-monoinfection (HIV,
n= 21), and seronegative controls (NC, n= 17). Exclusion criteria
included: active immunosuppressive therapy, active antiviral ther-
apy for HCV infection, HBV infection, autoimmune liver disease,
or significant medical comorbidities that preclude blood draws or
informed consent. Chronic HCV infection was defined by per-
sistent HCV viremia by quantitative RT-PCR by Roche COBAS
or TaqMan assays (Roche Diagnostics, Indianapolis, IN, USA) in
HCV-seropositive persons without acute hepatitis. HIV infection
was defined by detection of HIV Ab and/or HIV viral load. As
shown in Table 1, most patients were males in their 50s consis-
tent with our local patient population. Clinical liver-associated
parameters (e.g., bilirubin, albumin, platelet count, prothrombin
time INR, AST Platelet Ratio Index APRI) were largely preserved,
although sALT activity was greater in HCV and HCV/HIV groups
compared to HIV-monoinfected group. Majority of HIV-infected
patients were on anti-retroviral therapy and displayed HIV viral
load below 50 IU/ml.
ISOLATION OF PERIPHERAL BLOOD MONONUCLEAR CELLS
Peripheral blood mononuclear cell (PBMC) were isolated by
Ficoll-Histopaque (Sigma Chemical Co., St Louis, MO, USA) den-
sity centrifugation and used directly or cryopreserved as previously
described (33).
PEPTIDES AND HLA CLASS I TETRAMERS
HCV-specific T cell response was measured using a pool of
105 overlapping 15mer peptides spanning the entire HCV NS3
derived from HCV-H genotype 1a (34). HIV-specific T cell
response was measured using a pool of 124 overlapping 15mer
peptides spanning the entire HIV Gag (generously provided by
the AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH) (35). T cell response to influenza virus
was examined using 56 overlapping 15mer peptides spanning
the conserved matrix M1 protein (residues 1–252) based on the
human A/PR/8/34 (H1N1) virus. For HLA-A2+ subjects, the fol-
lowing peptides were synthesized for antigenic stimulation and
tetramer synthesis as described previously (6, 7): (i) HCV NS3
1073 (CINGVCWTV), NS3 1406 (KLVALGINAV), and NS5B 2594
(ALYDVVSKL); (ii) HIV Gag (SLYNTVATL); (iii) influenza matrix
(GILGFVFTL); (iv) EBV BMLF1 (GLCTLVAML); (v) CMV pp65
(NLVPMVATV).
FLUORESCENT ANTIBODIES
All monoclonal antibodies were purchased from BD Bioscience
(San Jose, CA, USA) except for anti-Foxp3 from eBioscience (San
Diego, CA, USA). Foxp3 and CTLA-4 expression was examined
using FITC-labeled αFoxp3 (clone PCH101, eBioscience) and PE-
labeled αCTLA-4 (αCD152; clone BNI3, BD). Dead cells were
excluded with 7AAD.
IMMUNOPHENOTYPING BY FLOW CYTOMETRY
Cells were stained by fluorescent antibodies as per manufacturer’s
instructions with freshly isolated PBMC used directly ex vivo (36).
Events were acquired with a FACSCanto (Becton Dickinson, San
Jose, CA, USA) and analyzed with FlowJo (Tree Star Inc., Ash-
land, OR, USA), gating on live lymphoid cells based on scatter
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characteristics and viability staining (7AAD by Biolegend or Aqua
LIVE/DEAD L34957 by Invitrogen) and single color compensation
controls. Intracellular FoxP3 and CTLA-4 expression was detected
after permeabilization with cutoffs determined by isotype controls
(Foxp3: 99.9%, CTLA-4: 99.9%) as previously described (6, 36).
The frequency of FoxP3+CD4+ Tregs (%Foxp3+CD4+/
lymphocytes) in total lymphocytes was measured as percentage of
FoxP3+CD4+ T cells in live lymphocyte gate. FoxP3+ Treg fre-
quency in CD4 T cells (%FoxP3+/CD4 T cells) was measured as
percentage of FoxP3+ cells within CD4+ live lymphocytes. Sim-
ilar strategies were used to define circulating frequency of CD4+
or CD8+ T cells expressing PD-1, CTLA-4, or CD28+ T cells in
total, CD4+ or CD8+ live lymphocytes.
ANALYSIS OF VIRUS-SPECIFIC T CELL IFNγ AND TNFα PRODUCTION IN
SHORT TERM T CELL LINE
PBL (2× 106 cells/ml/well in 24-well plate) were: (1) stimulated
with media, overlapping 15mer peptide pools (HCV NS3, HIV
Gag, or influenza matrix at 2 iM per peptide) on day 0; (2) supple-
mented by fresh media with rIL-2 (100 IU/ml) on day 3 or 4; (3)
examined by antigen-specific TNFα and IFNγ production on day
7 by intracellular cytokine staining as previously described (7).
ANALYSIS OF ANTIGEN-SPECIFIC T CELL EXPANSION AND EFFECTOR
FUNCTION IN THE PRESENCE OR ABSENCE OF PD-1 AND/OR CTLA-4
BLOCKADE
PBL (2× 106 cells/ml/well in 24-well plate) were stimulated with
overlapping HCV NS3, HIV Gag, or influenza matrix 15mer pep-
tide pools (2µM) in the presence of isotype control, aPD-L1 (clone
29E.2A3.C6), aCTLA-4 (clone BNI3; BD), or both aPD-L1 and
aCTLA-4 (10µg/ml for each mAb) as previously described (7).
Cell cultures were stimulated with rIL-2 (100 IU/ml) on day 3
or 4 and examined for cytokine production by flow cytometry
on day 7 after 6 h stimulation with and without HCV, HIV, or
Flu peptides in the presence of brefeldin A (10µg/ml) as pre-
viously described (7). Virus-specific responses were calculated
by subtracting the cytokine responses in media control samples
from peptide-stimulated samples during the intracellular cytokine
staining. A positive response to blockade was defined as antigen-
specific response that was greater than the isotype control condi-
tion by at least a standard deviation of the all background responses
(0.36%).
CYTOKINE ANALYSIS OF FoxP3+ AND FoxP3− T CELLS IN PBMC
EX VIVO
PBL (2× 106 cells/ml/well in 24-well plate) were stimulated with
or without overlapping HCV NS3, HIV Gag, influenza matrix
15mer peptide pools (2µM) or 10 ng/ml phorbol 12-myristate
13-acetate (PMA; Sigma Chemical Co.), 200 ng/ml ionomycin
(Sigma Chemical Co.) in the presence of brefeldin A (10µg/ml)
and FoxP3, and intracellular cytokine staining was performed after
5.5 h with a Cytofix/Cytoperm kit (BD Pharmingen) as previously
described (36).
IFNγ ELISPOT ASSAY
IFNγ Elispot assays were performed with 200,000 PBMCs per
well stimulated in triplicates by overlapping pHCV NS3, pHIV
Gag, or pFlu matrix 15mer peptide pools (2 mM) or media alone.
After 45 h, plates were developed and IFNg spot forming units
(SFUs) counted by an ELISPOT reader as previously described
(37). Antigen-specific IFNg+ T cells were quantified by subtract-
ing the mean IFNg SFUs in negative control wells from the mean
SFUs in antigen-stimulated wells and expressed as IFNγ SFUs/106
cells. A response was considered positive if it was above the cut-
off value calculated from negative control wells as average mean
SFU+ 3 standard deviations (57 SFUs/106 cells).
CELL SORTING
CD4+CD25+ and CD4+CD25− subsets were sorted by
autoMACS using the CD4+CD25+ regulatory T cell isolation
system (Miltenyi Biotec Inc., Auburn, CA, USA) as previously
described (36). FoxP3 expression in sorted CD4+CD25+ and
CD4+CD25− T cell subsets was determined by FACS to com-
pare direct FoxP3+ Treg frequency and effector T cell suppression
in subsequent ex vivo Treg suppression assay.
EX VIVO Treg SUPPRESSION ASSAY
AutoMACS-sorted CD4+CD25+:“suppressor”T cells were cocul-
tured in triplicate wells with autologous CD4+CD25− “respon-
ders” (60,000 cells/well) in 96-well plates at suppressor/responder
ratios of 1:0, 1:1,0.5:1,0.25:1, 0.125:1, and 0:1 for 3 days with media
alone, 2µg/ml phytohemagglutinin (PHA; Sigma Chemical Co.),
or 0.04µg/ml anti-CD3 (clone UCHT1; BD Pharmingen) with
2µg/ml anti-CD28 (clone CD28.2; BD Pharmingen) before 16 h
of [3H]thymidine (1µCi/well) uptake as previously described (7,
33, 36). Proliferation was expressed as a stimulation index (SI): the
mean cpm in stimulated wells divided by the mean cpm in unstim-
ulated wells. T cell proliferation in each coculture was normalized
by proliferation in CD4+CD25− T cells alone and compared to
the calculated percentage of FoxP3+CD4 T cells in each cocul-
ture condition, based on %FoxP3+ cells in CD4+CD25− and
CD4+CD25+ cell subsets determined by FACS.
STATISTICAL ANALYSIS
Clinical and immunologic parameters between patient groups
were compared by the non-parametric Mann–Whitney U test
or Kruskal–Wallis. With multiple two-way comparisons, P-values
were corrected for multiple comparisons. Pair-wise comparisons
were performed by paired t -test. Correlations were tested for sta-
tistical significance by Spearman rank correlation. P-values below
0.05 were considered significant.
RESULTS
FoxP3 EXPRESSION IS INCREASED IN CD4 T CELLS FROM
HCV/HIV-COINFECTED THAN HIV OR HCV-MONOINFECTED PATIENTS
Table 1 shows the demographic, clinical, and virological char-
acteristics of our patient groups with HCV (n= 20), HCV/HIV
(n= 23), and HIV (n= 21) infection. They were mostly males in
their 50s with preserved liver function (e.g., serum albumin, total
bilirubin, INR, and platelets). Majority of HCV-infected patients
had HCV genotype 1 infection, without significant differences in
HCV RNA titers between HCV and HCV/HIV groups (P = 0.98),
consistent with previous findings from our population (13). HIV
viral load was undetectable in 83% in HCV/HIV-coinfected and
in 61% in HIV-monoinfected patients (P = 0.10).
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FIGURE 1 | FoxP3+Tregs are enriched in CD4T cells from
HCV/HIV-coinfected patients. (A) Frequency of CD4 T cells among viable
lymphocytes is compared between 20 HCV-monoinfected (HCV), 23
HCV/HIV-coinfected (HCV/HIV), 21 HIV-monoinfected (HIV), and 17
seronegative control (NC) subjects. Horizontal bars indicate median values.
P -values are calculated with non-parametric Kruskal–Wallis for comparison
between all four groups and Mann–Whitney U for pair-wise comparisons.
Two-way comparison of HCV/HIV coinfection group with HCV or
HIV-monoinfection group was made using non-parametric Mann–Whitney U
and corrected for multiple comparisons. (B) Frequency of FoxP3+CD4 T cells
(FoxP3+Tregs) in CD4 T cells is compared between 20 HCV-monoinfected
(HCV), 23 HCV/HIV-coinfected (HCV/HIV), 21 HIV-monoinfected (HIV), and 17
seronegative control (NC) subjects. Horizontal bars indicate median values.
P -values are calculated with non-parametric Kruskal–Wallis for comparison
between all four groups and Mann–Whitney U for pair-wise comparisons.
Two-way comparison of HCV/HIV coinfection group with HCV or HIV
monoinfection group was made using non-parametric Mann–Whitney U and
corrected for multiple comparisons. (C) Left panel : representative FACS plots
are shown for FoxP3 and CD4 expression in live lymphocytes: Right panel :
frequency of FoxP3+CD4+T cells in total live lymphoid cells is compared
between 20 HCV-monoinfected (HCV), 23 HCV/HIV-coinfected (HCV/HIV), 21
HIV-monoinfected (HIV), and 17 seronegative control (NC) subjects. Horizontal
bars indicate median values. P -values are calculated with non-parametric
Kruskal–Wallis for comparison between all four groups and Mann–Whitney U
for pair-wise comparisons. Two-way comparison of HCV/HIV coinfection group
with HCV or HIV monoinfection group was made using non-parametric
Mann–Whitney U and corrected for multiple comparisons. (D) Phenotype of
FoxP3+CD4 T cells (filled black bars) and FoxP3− CD4 T cells (unfilled bars)
from HCV/HIV-coinfected patients are compared using percentage of cells
expressing CD25, CTLA-4, CD45RO, CD127, and CD69. (E) Percent
suppression of proliferation in AutoMACS-sorted CD4+CD25− “responder” T
cells alone and with increasing proportion of autologous CD4+CD25+
“suppressor” T cells enriched for FoxP3+CD4 T cells upon in vitro stimulation
with anti-CD3/CD28 or phytohemagglutinin (PHA) followed by 3H thymidine
uptake. Proliferation was expressed as a stimulation index (SI): the mean cpm
in stimulated wells divided by the mean cpm in unstimulated wells. T cell
proliferation in each coculture was normalized by proliferation in CD4+CD25−
T cells alone and compared to the calculated percentage of FoxP3+CD4 T
cells in each coculture condition, based on %FoxP3+ cells in CD4+CD25−
and CD4+CD25+ cell subsets determined by FACS.
We began by examining CD4 T cells for overall frequency and
FoxP3 expression. As expected, CD4 T cell frequency was lower
in HIV-infected subjects compared to HIV-uninfected subjects,
without a significant difference between HCV/HIV-coinfected
and HIV-monoinfected patients (P = 0.12) (Figure 1A). Notably,
FoxP3 expression was enriched in CD4 T cells from HCV/HIV-
coinfected patients both in frequency (HCV 8.9% vs. HCV/HIV
11.9% vs. HIV 8.5% vs. NC 7.5%, P < 0.0001) (Figure 1B) and
mean fluorescence intensity (MFI) (Figure S1 in Supplementary
Material) compared to other groups. Accordingly, FoxP3+CD4+
T cell frequency in the lymphocyte compartment was preserved in
HCV/HIV-coinfected patients compared to HCV-monoinfected
patients (3.2 vs. 3.5%, P = 0.12) despite lower CD4 T cell fre-
quency (Figure 1C). FoxP3+CD4+ T cells from HCV/HIV-
coinfected patients resembled natural Tregs with increased CD25,
CTLA-4, and CD45RO expression and reduced CD127 and CD69
expression (Figure 1D) as well as dose-dependent suppression of
CD4+CD25− T cell proliferation in vitro (Figure 1E) as pre-
viously described for HCV-monoinfected patients (36). Thus,
HCV/HIV coinfection was associated with an enrichment of
FoxP3+ subsets within the CD4 T cell compartment and relative
preservation of FoxP3+ Tregs in circulating lymphocytes.
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FIGURE 2 |T cell expression levels of PD-1 and/or CTLA-4 associate with
FoxP3+Tregs in patients with HCV and/or HIV infection. (A) Frequency of
CD4 and CD8 T cells expressing CTLA-4, PD-1, CD28, or CD127 are compared
between 10 HCV-monoinfected (C), 9 HCV/HIV-coinfected (C/I), 10
HIV-monoinfected (I), and 10 seronegative control subjects (N). Horizontal
bars indicate median values. P -values are calculated with non-parametric
Kruskal–Wallis for comparison between all four groups. Two-way comparison
of HCV/HIV coinfection group with HCV or HIV monoinfection group was
made using non-parametric Mann–Whitney U and corrected for multiple
comparisons. P -values above 0.05 before correction are shown as “ns” or
“not significant.” (B) Frequency of CD4 and CD8 T cells expressing CTLA-4,
PD-1, CD28, or CD127 are correlated with FoxP3+Treg frequency in the CD4
T cell compartment, with non-parametric Spearman rank-order correlation and
P -values.
T CELLS FROM HIV/HCV-COINFECTED PATIENTS DISPLAY
DYSREGULATED EXPRESSION OF INTRINSIC T CELL CO-STIMULATORY
RECEPTORS IN ASSOCIATION WITH FoxP3+ Treg FREQUENCY
The effect of differential FoxP3+ Treg enrichment on intrinsic
T cell inhibitory (CTLA-4, PD-1) and co-stimulatory (CD28 and
CD127) receptors was further examined in a subset of subjects with
available lymphocytes. As shown in Figure 2A and Table 2, there
were significant phenotypic differences in T cell subsets from the
patient groups relative to HCV and/or HIV infection. First, CTLA-
4 expression in CD4 T cells resembled FoxP3 in that it was highest
in HCV/HIV-coinfected patients compared to other groups. Sec-
ond, expression levels of PD-1, CD28, and CD127 in CD4 T cells
were largely linked to HIV infection. For example, CD4 T cells in
HCV/HIV-coinfected and HIV-monoinfected patients displayed
PD-1 expression at twofold higher level compared to CD4 T cells
from HIV-uninfected patients (Table 2). Furthermore, CD4 T
cells from HCV/HIV-coinfected and HIV-monoinfected patients
displayed more subtle but significantly lower CD28/CD127 expres-
sion compared to CD4 T cells from HIV-uninfected patients.
Third, CTLA-4, CD28, and CD127 expression levels in CD8 T cells
were significantly lower in HIV-infected than in HIV-uninfected
patients. Finally, FoxP3+ Treg frequency correlated directly with
CTLA-4 expression in CD4 T cells as expected (Figure 2B) but
also with PD-1 expression in CD4 T cells as well as CTLA-4 and
CD28 expression in CD8 T cells (Figure 2B).
We further examined expression of PD-1 and CTLA-4 in
FoxP3+ Tregs. As shown in Figure 3, PD-1 expression differed
significantly between the four patient groups, without signifi-
cant differences for CTLA-4. There was no significant difference
between the groups in CD28 or CD127 expression in FoxP3+Tregs
(data not shown). Differential PD-1 expression by FoxP3+ Tregs
was based on HIV infection, as FoxP3+ Tregs displayed twofold
higher PD-1 expression than FoxP3+ Tregs from HIV-infected
patients (44 vs. 28%, P = 0.0017) (Table 2). Thus, HCV/HIV
coinfection was associated with global dysregulation in T cell phe-
notype in association with FoxP3+Treg frequency, with both HCV
and HIV-mediated effects.
FoxP3+ Treg FREQUENCY AND GLOBAL T CELL EXPRESSION OF
INTRINSIC CO-STIMULATORY RECEPTORS CORRELATE WITH CD4 T
CELL FREQUENCY
Inverse association between FoxP3+ Treg frequency and CD4
T cell frequency was previously reported in HIV-monoinfected
patients (23). In our study, inverse correlation between FoxP3+
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Table 2 | Phenotype comparison of CD4 and CD8T cells from HIV+ and
HIV− subjects.
HIV+ HIV−
Median SD Median SD *P -value
A. CD4T CELLS
%PD1+ 30.9 7.6 15.9 12.8 0.0001
%CTLA4+ 6.5 1.6 5.3 4.1 0.06
%CD28+ 93.3 3 98.8 13.1 0.0005
%CD127+ 82.5 3.9 88.7 9.8 0.0024
B. CDST CELLS
0/0PDI+ 26.2 9 18.5 12.8 0.112
%CTLA4+ 1.2 0.6 2.2 0.7 0.0003
%CD28+ 49.6 17.3 77.8 19.8 0.0001
<VoCD127+ 53.9 16.8 78.8 20.8 0.0003
C. FoxP3+CD4+T CELLS
%PD1+ 44 9.7 28 12.3 0.0017
%CTLA4+ 53 12.6 50 10.7 0.98
%CD28+ 98 0.9 99 8.9 0.06
%CD127+ 25 15.2 20 11.6 0.81
*P-values by non-parametric Mann–Whitney U.
SD, standard deviation.
Treg and CD4 T cell frequencies was also seen in HCV/HIV-
coinfected patients as well as HIV-monoinfected patients
(Figure 4A). This correlation became even stronger when results
from all groups including uninfected controls were combined
(Figures 4A,B far right). However, FoxP3+ Treg frequencies
remained higher in HCV/HIV-coinfected than HIV-monoinfected
patients in a subgroup analysis with lower or higher CD4 T cell
frequencies based on a median cutoff (31%) (Figure 4C). This
difference was also visually apparent by higher clustering of data
points from HCV/HIV-coinfected patients on the y-axis (red dia-
monds) compared to those from HIV-monoinfected patients (blue
triangles) (far right graph on Figure 4A).
Nevertheless, FoxP3+ Treg frequency in total lymphocytes
decreased as overall CD4 T cell frequency declined (Figure 4D).
Finally, global CTLA-4 and PD-1 expression in CD4 but not CD8 T
cells correlated inversely with overall CD4 T cell frequency whereas
CD28 and CD127 expression in both CD4 and CD8 T cells cor-
related directly with CD4 T cell frequency (Figure 4E). Thus,
FoxP3+ Treg frequency was significantly associated with CD4 T
cell frequency, which was further linked to T cell expression of
multiple inhibitory and co-stimulatory receptors.
FoxP3 EXPRESSION IN CD4 T CELLS IS NOT ASSOCIATED WITH LIVER
FUNCTION PARAMETERS OR LEVEL OF HIV/HCV VIREMIA
Despite its significant associations with CD4 T cell frequency
and global T cell phenotype, FoxP3+ Treg frequency did not
correlate with serum HCV RNA titers or liver function para-
meters (Figure S2A in Supplementary Material). Similarly, T
cell expression of PD-1, CTLA-4, or CD28 did not correlate
with HCV RNA titers or clinical liver function parameters (data
not shown). As previously reported (38–41), age was posi-
tively associated with FoxP3+ Treg frequency (Figure S2B in
FIGURE 3 | FoxP3+Treg expression levels of PD-1 and/or CTLA-4 in
patients with HCV and/or HIV infection. (A) Frequency of FoxP3+Tregs
expressing CTLA-4 and PD-1 are compared between 10 HCV-monoinfected
(C), 9 HCV/HIV-coinfected (C/I), 10 HIV-monoinfected (I), and 10
seronegative control subjects (N ). Horizontal bars indicate median values.
P -values are calculated with non-parametric Kruskal–Wallis for comparison
between all four groups. Two-way comparison of HCV/HIV coinfection
group with HCV or HIV monoinfection group was made using
non-parametric Mann–Whitney U and corrected for multiple comparisons.
(B) Relative frequencies of cells expressing PD-1 in FoxP3+CD4 T cells and
FoxP3−CD4 T cells are compared in a representative FACS overlay on the
left panel (FoxP3+CD4 T cells as red dot plot, FoxP3− CD4 T cells in blue
density plot) and in pair-wise comparison in 10 HCV, 9 HCV/HIV, 10 HIV, and
10 seronegative control. P -value is calculated by paired t -test.
Supplementary Material) but not with CD4 T cell frequency or
co-stimulatory receptor expression on CD4 and CD8 T cells (data
not shown). We also did not find an association between HIV
viral load and FoxP3+ Treg frequency. For example, FoxP3+
Treg frequency did not differ between HIV-seropositive patients
with and without active HIV viremia (Figure S2C in Supple-
mentary Material, left panel). Furthermore, FoxP3+ Treg fre-
quency did not correlate with HIV viral load among actively
HIV-viremic patients (Figure S2C in Supplementary Material,
middle panel), and it remained higher in HCV/HIV-coinfected
patients with undetectable HIV viremia compared to HIV-
monoinfected patients with undetectable HIV viremia and HCV-
monoinfected patients (Figure S2C in Supplementary Material,
right panel).
VIRUS-SPECIFIC EFFECTOR T CELL RESPONSES IN
HCV/HIV-COINFECTED PATIENTS DO NOT CORRELATE WITH FoxP3+
Treg FREQUENCY OR IMMUNE INHIBITORY RECEPTOR EXPRESSION
LEVELS ON T CELLS
Effector T cell responses to HCV NS3, HIV Gag, and influenza
matrix peptides were compared between the patient groups with
IFNγ Elispot ex vivo (Figure 5A) and with short term in vitro
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FIGURE 4 | Circulating CD4T cell frequency is associated with FoxP3,
PD-1, CTLA-4, and CD28 expression onT cell subsets. (A) Frequency of
FoxP3+Tregs in CD4 T cell compartment is compared with overall CD4 T
cell frequency in live lymphocytes for each patient group and with all
groups combined with 20 HCV-monoinfected (HCV), 23 HCV/HIV-coinfected
(HCV/HIV), 21 HIV-monoinfected (HIV), and 17 seronegative control (NC)
subjects. Spearman rank-order correlation and P -values are shown.
(B) FoxP3 mean fluorescence intensity (MFI) is compared with overall CD4
T cell frequency in live lymphocytes. Spearman rank-order correlation and
P -values are shown. (C) Frequency of FoxP3+Tregs in CD4 T cell
compartment is compared between in HCV/HIV-coinfected and
HIV-monoinfected patients with CD4 T cell frequency below or higher than
a cutoff of 31% (median CD4 T cell frequency). P -values are calculated by
non-parametric Mann–Whitney U test. (D) Frequency of FoxP3+CD4+T
cells in live lymphocyte compartment is compared with CD4 T cell
frequency with Spearman rank-order correlation and P -values. (E) CTLA-4,
PD-1, CD28, and CD127 mean fluorescence intensities (MFI) in CD4 and
CD8 T cells are compared with overall CD4 T cell frequency in live
lymphocyte compartment. Spearman rank-order correlation and P -values
are shown.
culture followed by intracellular cytokine staining (Figures 5B,C).
In general, T cell response to HCV was weak in HCV-infected
patients, whereas T cell response to HIV was more readily detected
in HIV-infected patients (Figures 5A,B). In particular, HCV/HIV-
coinfected patients displayed weak to undetectable T cell IFNγ
response to HCV that contrasted with HIV-specific T cell IFNγ
responses that were readily detected at levels similar to HIV-
monoinfected patients (Figures 5A–C). Relevant for immune
regulatory pathways, T cell IFNγ responses to HCV, HIV, or
influenza peptides did not correlate with FoxP3+ Treg frequency
(Figure 5D) or T cell expression of PD-1 or CTLA-4 (data not
shown).
We then examined if blockade of PD-1 and/or CTLA-4 with
anti-PDL1 and anti-CTLA-4 could enhance virus-specific effec-
tor T cell responses in 11 HCV/HIV-coinfected patients. As
shown in Figures 6A–C, anti-PD-1 augmented HIV-specific CD8
T cell response in 3/11 patients and HIV-specific CD4 T cell
response in 5/11 patients. By contrast, PD-1 blockade augmented
HCV-specific CD8 T cell responses in 0/11 patients and HCV-
specific CD4 T cell response in 1/11 patients. This resulted in
anti-PDL1-mediated augmentations for 8/22 HIV-specific T cell
responses and 1/22 HCV-specific T cell response (36 vs. 4.5%,
P = 0.02). As for CTLA-4 blockade, there was no augmentation
for HCV-specific T cell responses compared to 3/22 HIV-specific
T cell responses (0 vs. 14%, P =NS). Augmentations were also
observed for Flu-specific CD4 T cell response upon CTLA-4
but not PD-1 blockade. Combined PD-1/CTLA-4 blockade did
not further enhance antiviral T cell function (data not shown),
consistent with our previous study regarding peripheral blood
compartment (6, 7).
Collectively, we show that multiple immune regulatory path-
ways are induced in HCV/HIV coinfection including FoxP+Tregs,
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FIGURE 5 |T cell cytokine responses to HCV, HIV, and Flu peptides.
(A) Median T cell IFNγ responses and percent positive responders to HCV,
HIV, and Flu peptides in HCV, HCV/HIV, and HIV-infected patient groups are
shown in log scale (log spot forming units per million PBMC) based on IFNγ
ELISPOT assay using PBMCs stimulated ex vivo with overlapping 15mer
peptide pools spanning HCV NS3 (pHCV), HIV Gag (pHIV), and influenza
matrix (pFlu). Unfilled bar (HCV-monoinfected, n= 6), black bar
(HCV/HIV-coinfected, n=6), gray bar (HIV-monoinfected, n= 5). Positive
responses were defined by cutoff values for each assay (>average
background+3 SDs). P -values comparing three groups were calculated by
non-parametric Kruskal–Wallis with only significant difference seen for
HIV-specific T cell response (both by SFU and % responders) due to lack of
HIV-specific T cell response in HCV-monoinfected patients. (B) Frequency of
CD8+T cells with antigen-specific IFNγ production in short term PBMC
cultures is shown from HCV/HIV-coinfected patients, HCV-monoinfected,
and HIV-monoinfected patients. PBMC cultures were stimulated for 7 days
with overlapping peptide pools (2µM) and rIL-2 followed by further 5.5 h
peptide stimulation in the presence of Brefeldin A, intracellular cytokine
staining, and FACS analysis. Total of 8 HCV/HIV-coinfected patients, 11
HCV-monoinfected, and 9 HIV-monoinfected patients were included, with
sample size for each stimulation condition shown as defined by available
lymphocytes. Red dotted line indicates the 0.27%, which was the cutoff
value for a positive response based on average background+3 SDs. Positive
responses above 0.27% are further highlighted as dark shaded diamonds.
P -values comparing two groups were calculated by non-parametric
Mann–Whitney U without significant differences between the groups.
(C) Representative FACS plots show TNFα and IFNγ expression in
CD8-gated cells from an HCV/HIV-coinfected (C423) and HIV-monoinfected
(I026) subjects. (D) Peptide-specific IFNγ response (in spot forming units
per million PBMC) is compared with the frequency of FoxP3+Tregs in CD4
T cell compartment from HCV/HIV-coinfected patients. Spearman rank-order
correlation and P -values are shown without significant associations.
PD-1, and CTLA-4 in significant association with HIV-associated
CD4 T cell loss and with apparent suppression of effector T cell
responses against HIV but not HCV.
DISCUSSION
Effector functions of virus-specific CD8 T cells are regulated
by extrinsic immune regulatory pathways including Tregs and
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FIGURE 6 | Effect of in vitro PD-1 blockade on virus-specificT cell
cytokine responses in HCV/HIV-coinfected patients. T cell cytokine
responses (combining IFNγ and/or TNFα responses) to HCV, HIV, and Flu
peptides were examined in HCV/HIV-coinfected patients with and without
PD-1 and/or CTLA-4 blockade in vitro. PBMCs from HCV/HIV-coinfected
patients were cultured for 7 days in vitro with pHCV NS3, pHIV GAG, or pFlu
Matrix in the presence of isotype control or blocking antibodies. The 7-day
cultures were further stimulated for 6 h with media alone or with each peptide
before intracellular IFN-γ and TNF-α staining. Virus-specific responses were
calculated by subtracting the cytokine responses in media control samples
from peptide-stimulated samples during the intracellular cytokine staining. A
positive response to blockade was defined as antigen-specific response that
was greater than the isotype control condition by at least a standard deviation
of the all background responses (0.36%). (A) Percentage of virus-specific
cytokine+ cells in CD8 (left panel) and CD4T cells (right panel) are shown from
HCV/HIV-coinfected patients, comparing responses with isotype antibody and
with anti-PDL1 blocking Ab (10µg/ml). Significant P -value per paired t -test is
shown for HIV Gag. Assay pairs with augmented responses to PD-1 blockade
above isotype control condition are highlighted as red lines. Significant
increase in cytokine response by PD-1 blockade is shown for HIV-specific CD8
T cells (P =0.047) via paired t -test. (B) Percentage of positive responders
(augmentations above 0.36%) to anti-PDL1 or anti-CTLA-4 is shown for
virus-specific CD8 (left panel) and CD4 T cells (right panel) from
HCV/HIV-coinfected patients. Significant anti-PDL1-mediated augmentation is
shown for HIV-specific CD4 T cell response by Kruskal–Wallis (P =0.037).
(C) Representative FACS plots are shown for HIV Gag-specific IFN-γ andTNF-α
production in CD8 (left) and CD4 T cells (right) in short term PBMC culture
from HCV/HIV-coinfected patients, following 7 day culture with HIV peptides
in the presence of either isotype antibody or anti-PDL1. Marked induction in
IFNγ and TNFα responses is apparent for CD4 T cells following PD-1 blockade.
cytokines as well as intrinsic expression of immune modulatory
molecules (9, 42–45). In viral infections, these regulatory path-
ways can limit the extent of cellular injury but also promote viral
survival with long-term pathogenetic consequences. In particular,
HCV persists with functionally impaired HCV-specific effector T
cells that over-express PD-1, CTLA-4, and/or Tim-3 (6, 7, 45–47)
and increased circulating FoxP3+ Tregs that are indistinguish-
able from natural Tregs (33, 36, 48, 49). Treg development and
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function may in turn be influenced by PD-1 and CD28 (17, 50).
Further complexity is expected in HCV/HIV coinfection due to
HIV-mediated immune effects as well as Treg dynamics (23, 51).
For example, PD-1 and CTLA-4 expression in antiviral T cells
correlated with HIV viral load and CD4 T cell count in HIV-
monoinfected patients (3–5). With HCV/HIV coinfection, Treg
induction has been related to HIV rather than HCV (24, 30)
whereas PD-1/Tim-3 co-expression in both total and HCV-specific
T cells associated with liver-related outcomes (52). In this study,
the interplay between Tregs and intrinsic co-stimulatory path-
ways in HCV/HIV coinfection was examined with the hypothesis
that HCV/HIV coinfection will heighten immune dysregulation
associated with chronic viral infection.
In fact, FoxP3+Treg frequency in total lymphocytes was similar
between HCV/HIV-coinfected and HCV-monoinfected patients
despite almost twofold difference in CD4 T cell frequency between
HCV/HIV-coinfected and HCV-monoinfected patients. This was
due to significantly enriched FoxP3 expression in CD4 T cells
from HCV/HIV-coinfected patients compared to other groups.
Increased FoxP3 expression in CD4 T cells from HCV/HIV-
coinfected patients was not due to active HIV viremia since most
patients (83%) had HIV viral load below detection limit. FoxP3+
Tregs from HCV/HIV-coinfected patients generally resembled nat-
ural Tregs in phenotype and suppressive function (Figure 1). How-
ever, FoxP3+ Tregs from HCV/HIV-coinfected patients (as well as
HIV-monoinfected patients) displayed increased PD-1 expression
compared to Tregs from HIV-uninfected subjects, suggesting that
HIV-mediated immune activation extends to FoxP3+ Tregs.
Perhaps due to the preserved FoxP3+ Treg frequency in total
lymphocytes, there was no significant association between FoxP3+
Treg frequency and HCV-associated liver disease parameters or
HCV RNA titers. However, FoxP3 expression in CD4 T cells
was inversely correlated with overall CD4 T cell frequency, a
critical marker of immune competence. While this inverse asso-
ciation was previously reported in HIV-monoinfected patients
(23), our study further extends this association to HCV/HIV-
coinfected patients. Perhaps more interestingly, the inverse associ-
ation between CD4 T cell frequency and FoxP3+ Treg frequency
became even stronger when all subjects (including the unin-
fected controls) were included (rs=−0.64, P < 0.000001). This
suggested a more generalized homeostatic mechanism to sustain
FoxP3+ Treg frequency as CD4 T cell frequency declines. This
possibility was previously reported for cancer patients undergoing
chemotherapy (53), but may be more generalized based on our
findings. In this regard, HIV-mediated CD4 T cell loss may play
a dominant effect on FoxP3+ Treg dynamics to preserve the total
circulating FoxP3+Tregs (24, 30), although this is insufficient with
progressive HIV-associated CD4 T cell loss.
The main finding in our study is that multiple immune
inhibitory pathways are induced HCV/HIV-coinfected patients
due to HCV and/or HIV infection, despite therapeutic HIV
suppression. At the same time, both CD4 and CD8 T cells in
HCV/HIV-coinfected patients showed reduced expression of posi-
tive co-stimulatory receptor CD28 and IL7 receptor alpha CD127.
FoxP3+ Treg frequency correlated with expression of PD-1 and
CTLA-4 on CD4 T cells as well as CTLA-4 and CD28 expres-
sion on CD8 T cells. These associations are likely linked to CD4
T cell frequency in which CD4 T cell loss occurs with preferen-
tial induction of multiple inhibitory pathways in CD4 (but not
CD8) T cells and reduction in CD28 and CD127 expression for
both CD4 and CD8 T cells. It is not clear if these changes are the
cause or consequence of CD4 T cell loss. Furthermore, immune
inhibitory induction despite apparent therapeutic HIV suppres-
sion suggests that virus control is not absolute and that there is
ongoing HIV-associated immune activation.
Blockade of one or more co-stimulatory receptor including
PD-1, CTLA-4, Tim-3, and 4-1BB has been shown to enhance
virus-specific T cell function in chronic viral infections including
HCV, HBV, HIV, and SIV (2–12, 31). Better understanding of these
pathways has therapeutic implications, given the available agents
to modulate these pathways to treat chronic viral infection and
enhance tumor immunity. For example, PD-1 blockade in vivo
improved control of SIV in vivo with enhanced gut immunity,
reduced microbial translocation, and survival of SIV-infected rhe-
sus macaques (11, 12). Furthermore, PD-1 blockade in vivo was
well-tolerated and promoted virus control in a subset of HCV-
infected patients (54) whereas CTLA-4 blockade in patients with
hepatocellular carcinoma and chronic hepatitis C was tolerated
with antiviral and immune stimulatory effects (32). Our findings
in HCV/HIV-coinfected patients show that co-stimulatory recep-
tor blockade was more effective for T cell responses to HIV than
HCV. This may in part reflect the underlying frequency as well
as functionality of HCV-specific T cells. Since most HCV/HIV-
coinfected patients in our study had therapeutic suppression of
HIV (but not HCV), HIV-specific T cells may have been less
exhausted and paradoxically more responsive to co-stimulatory
blockade than HCV-specific T cells. In this regard, we previously
showed that PD-1 blockade was less effective for highly exhausted
HCV-specific T cells isolated from HCV-infected liver (6, 7). Alter-
natively, HCV-specific effector T cells may be poorly maintained in
HCV/HIV-coinfected patients due to HIV-associated CD4 T cell
dysfunction and immune inhibition. It is also possible that HCV
and HIV reside in different compartments although we previously
showed that in vitro PD-1 blockade of PBMC can enhance HCV-
specific effector T cell function in four/six HCV-infected patients
(6).
Collectively, we show that multiple T cell inhibitory pathways
are induced in patients with HCV/HIV coinfection. These changes
were inversely associated with circulating CD4 T cell frequencies
as a consequence of HIV infection, but not with viral titers or
HCV-associated liver function parameters. In vitro PD-1 blockade
of PBMC from HCV/HIV-coinfected patients restored effector T
cell responses to HIV but not HCV with less prominent impact by
CTLA-4 blockade. These findings provide new insights on inter-
play between extrinsic and intrinsic immune regulatory pathways
as well as virus-specific effect of co-stimulatory receptor blockade
relevant for immunotherapeutic development.
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